Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 878 across all filing types
Latest filing 2026-05-11 Declaration of Voting R…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax annonce les résultats de son Assemblée Générale du 11 mai 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is an announcement of the results of an Annual General Meeting held on 11 May 2026, detailing that shareholders approved the resolutions and where detailed voting results will be available. It does not present financial statements or detailed presentation materials, but rather the official voting outcomes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-11 French
Abivax annonce les resultats de son Assemblee Generale du 11 mai 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a press release reporting the results of an Annual General Meeting held on 11 May 2026, detailing shareholder votes on proposed resolutions (approval of accounts, remuneration policy, delegated authorities). It does not contain financial statements or act as the report itself but rather announces the voting outcomes. This matches the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA).
2026-05-11 French
Franchissements de seuils
Major Shareholding Notification Classification · 92% confidence The document is an AMF "Déclaration de franchissements de seuils" (threshold crossing declaration) indicating that JP Morgan Chase & Co. has crossed the 5% shareholding threshold in ABIVAX. This clearly falls under a Major Shareholding Notification, not an insider deal or dividend notice.
2026-05-11 French
Franchissements de seuils
Major Shareholding Notification Classification · 98% confidence The document is a formal French AMF declaration of crossing shareholding thresholds under article L.233-7 of the French commercial code, detailing that JP Morgan Chase & Co. has fallen below the 5% threshold in ABIVAX shares and providing precise share counts and voting rights. This matches the definition of a Major Shareholding Notification.
2026-05-11 French
Franchissements de seuils
Major Shareholding Notification Classification · 95% confidence The document is a formal notification filed under French commercial code articles L.233-7 and related AMF regulations detailing threshold crossings (declared decreases and increases around the 5% ownership level) by JP Morgan Chase & Co. in ABIVAX capital and voting rights. This exactly matches a Major Shareholding Notification (crossing thresholds).
2026-05-11 French
Abivax annonce le rachat des Certificats de Royalties et les modalités définitives de l’émission de 45M$ (38,5M€) d'American Depositary Shares
Regulatory Filings
2026-05-05 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.